{"id":33287,"date":"2021-12-22T15:49:10","date_gmt":"2021-12-22T15:49:10","guid":{"rendered":"https:\/\/insights.greyb.com\/?post_type=ht_kb&p=33287"},"modified":"2025-09-24T02:31:35","modified_gmt":"2025-09-24T02:31:35","slug":"theranos-patents","status":"publish","type":"ht_kb","link":"https:\/\/insights.greyb.com\/theranos-patents\/","title":{"rendered":"Theranos Patents \u2013 Insights & Stats (Updated 2025)"},"content":{"rendered":"\n

Theranos has a total of 392 patents globally, out of which 148 have been granted. Of these 392 patents, more than 28% patents are active. Mexico is where Theranos has filed the maximum number of patents, followed by New Zealand and Korea (South). Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Theranos.<\/p>\n\n\n\n

Theranos was founded in the year 2003. The company runs clinical labs that focus on medical testing. The company provides services mainly in cancer care, children’s health, and elderly care. It aims to make blood testing easier, faster, and more accessible. By using advanced technology, Theranos works to improve healthcare and offer accurate results with minimal discomfort for patients.<\/p>\n\n\n\n

Do read about some of the most popular patents of Theranos which have been covered by us in this article and also you can find Theranos patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Theranos patent portfolio.<\/p>\n\n\n\n

How many patents does <\/strong>Theranos <\/strong>have?<\/strong><\/h3>\n\n\n\n

Theranos has a total of 392 patents globally. These patents belong to 60 unique patent families. Out of 392 patents, 110 patents are active.<\/p>\n\n\n\n

How Many Patents did <\/strong>Theranos <\/strong>File Every Year?<\/strong><\/h3>\n\n\n\n
\"Theranos<\/a><\/figure>\n\n\n\n

Are you wondering why there is a drop in patent filing for the last two years? <\/strong>It is because a patent application can take up to 18 months to get published. Certainly, it doesn\u2019t suggest a decrease in the patent filing.<\/p>\n\n\n\n

Year of Patents Filing or Grant<\/strong><\/td>Theranos Applications Filed<\/strong><\/td>Theranos Patents Granted<\/strong><\/td><\/tr>
2024<\/td>–<\/td>1<\/td><\/tr>
2023<\/td>–<\/td>1<\/td><\/tr>
2022<\/td>–<\/td>2<\/td><\/tr>
2021<\/td>1<\/td>–<\/td><\/tr>
2019<\/td>1<\/td>–<\/td><\/tr>
2018<\/td>4<\/td>51<\/td><\/tr>
2017<\/td>4<\/td>26<\/td><\/tr>
2016<\/td>61<\/td>17<\/td><\/tr>
2015<\/td>70<\/td>12<\/td><\/tr>
2014<\/td>86<\/td>14<\/td><\/tr>
2013<\/td>43<\/td>10<\/td><\/tr>
2012<\/td>22<\/td>8<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

How many Theranos<\/strong> <\/strong>patents are Alive\/Dead?<\/strong><\/h3>\n\n\n\n

Worldwide Patents<\/strong><\/strong><\/p>\n\n\n\n

\"Theranos<\/a><\/figure>\n\n\n\n

How Many Patents did <\/strong>Theranos <\/strong>File in Different Countries?<\/strong><\/strong><\/h3>\n\n\n\n
\"Theranos<\/a><\/figure>\n\n\n\n

Countries in which <\/strong>Theranos <\/strong>Filed Patents<\/strong><\/h3>\n\n\n\n
Country<\/strong><\/td>Patents<\/strong><\/td><\/tr>
Mexico<\/td>35<\/td><\/tr>
New Zealand<\/td>34<\/td><\/tr>
Korea (South)<\/td>33<\/td><\/tr>
India<\/td>28<\/td><\/tr>
Europe (EPO)<\/td>27<\/td><\/tr>
South Africa<\/td>24<\/td><\/tr>
Singapore<\/td>24<\/td><\/tr>
Japan<\/td>20<\/td><\/tr>
United Kingdom<\/td>18<\/td><\/tr>
United States of America<\/td>15<\/td><\/tr>
Austria<\/td>14<\/td><\/tr>
Australia<\/td>11<\/td><\/tr>
Spain<\/td>9<\/td><\/tr>
Russian Federation<\/td>5<\/td><\/tr>
Poland<\/td>4<\/td><\/tr>
Canada<\/td>3<\/td><\/tr>
Taiwan<\/td>3<\/td><\/tr>
Hong Kong (S.A.R.)<\/td>2<\/td><\/tr>
Brazil<\/td>2<\/td><\/tr>
China<\/td>1<\/td><\/tr>
Malaysia<\/td>1<\/td><\/tr>
Denmark<\/td>1<\/td><\/tr>
Israel<\/td>1<\/td><\/tr>
Argentina<\/td>1<\/td><\/tr>
Thailand<\/td>1<\/td><\/tr>
Portugal<\/td>1<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Where are Research Centres of <\/strong>Theranos <\/strong>Patents Located?<\/strong><\/h3>\n\n\n\n
\"R&D<\/a><\/figure>\n\n\n\n

<\/strong>10 Best <\/strong>Theranos <\/strong>Patents<\/strong><\/strong><\/h3>\n\n\n\n

US20120309636A1<\/a> is the most popular patent in the Theranos portfolio. It has received 300 citations so far from companies like Gauss Surgical, Qualigen Inc and Cerner Innovation Inc.<\/strong><\/p>\n\n\n\n

Below is the list of 10 most cited patents of Theranos:<\/strong><\/p>\n\n\n\n

Publication Number<\/strong><\/td>Citation Count<\/strong><\/td><\/tr>
US20120309636A1<\/a><\/td>300<\/td><\/tr>
US20090318775A1<\/a><\/td>246<\/td><\/tr>
WO2013052318A1<\/a><\/td>227<\/td><\/tr>
US20140170735A1<\/a><\/td>198<\/td><\/tr>
US20130074614A1<\/a><\/td>127<\/td><\/tr>
US20060264783A1<\/a><\/td>127<\/td><\/tr>
WO2014127379A1<\/a><\/td>112<\/td><\/tr>
US20060264779A1<\/a><\/td>111<\/td><\/tr>
WO2013043203A2<\/a><\/td>98<\/td><\/tr>
US20130080071A1<\/a><\/td>94<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Theranos claimed to have invented devices that use tiny blood volumes to automate and miniaturize blood tests. Theranos’ blood collecting vessel was dubbed the “nanotainer,” while its analysis machine was dubbed the “Edison.”<\/p>\n\n\n\n

The company rose to prominence by providing blood tests that required fewer blood samples that could be taken at home in a less intrusive manner than currently available methods. Theranos claimed to have spent over a decade developing a breakthrough proprietary technology while operating in “stealth mode.”<\/p>\n\n\n\n

The capacity to deliver on the promise of requiring less blood for analysis was a major factor in developing an effective testing method. The testing technique was expected to be significantly reliant on data, and the examination of fresh samples was supposed to develop the entire testing system. As a result, expanding the firm may theoretically improve the machines that analyse the samples because the sample size they worked with grew, allowing the technology to become more precise. By simplifying testing and targeting non-consumers, Theranos aimed to disrupt the laboratory sector as we know it. Servicing the non-consumption sector would result in ever-growing data pools, which would lead to improved testing, analysis, and diagnosis.<\/p>\n\n\n\n

EXCLUSIVE INSIGHTS COMING SOON<\/strong>!<\/p>\n\n\n\n

What are Theranos\u2019s key innovation segments?<\/strong><\/h3>\n\n\n\n\n